BioCentury
ARTICLE | Finance

Ebb & Flow

June 11, 2007 7:00 AM UTC

The Street had a mixed reaction to the pair of private companies that Amgen (AMGN) picked up last week. One of them seems to be a close fit with AMGN's existing products and sales strategy in renal indications, while the diabetes deal stretches the company into relatively unfamiliar and expensive terrain for general practitioners.

Moreover, the lead compounds from both deals won't be first to market in their class...